dRVVT Screen

If you have had an unexplained blood clot, a stroke at a young age, or repeated pregnancy loss, this is one of the tests that can tell you whether your body is making an antibody that quietly tips your blood toward clotting. The dRVVT (dilute Russell's viper venom time) screen is the most widely used first step in checking for that antibody, called lupus anticoagulant.

This is a targeted diagnostic test, not a routine wellness number. It does not show up on a standard blood panel, and a normal CBC, PT, or aPTT does not rule it out. No single assay catches every lupus anticoagulant, so dRVVT is normally paired with a second lupus anticoagulant-sensitive test, and the result only makes sense in context, interpreted by a clinician who knows how to read it.

What This Test Actually Measures

The dRVVT screen is not a molecule in your blood. It is a functional clotting test. The lab adds a snake venom protein (from Russell's viper) plus a small amount of fat-like material called phospholipid to your plasma, then times how long it takes to clot. The venom forces clotting to depend on phospholipid, which is exactly the surface that lupus anticoagulant antibodies block.

If a lupus anticoagulant antibody is present, the clotting time stretches out. A separate confirm step then repeats the test with extra phospholipid added. If the clotting time shortens with more phospholipid, that pattern points to a real lupus anticoagulant rather than another cause of slow clotting. The gap between the screen and the confirm carries more meaning than the screen number on its own.

Why Lupus Anticoagulant Matters

Lupus anticoagulant is one of the antibodies that defines antiphospholipid syndrome, an autoimmune condition that promotes clotting in veins and arteries and causes pregnancy complications. The name is misleading. Despite the word anticoagulant, in the body these antibodies push you toward more clotting, not less.

In people with systemic lupus, a positive dRVVT was the strongest predictor of thrombosis, with about six times the odds of having a clotting event compared to those who tested negative (odds ratio 6.1, 95% CI 3.5 to 10.3). In non-lupus autoimmune disease, dRVVT positivity was linked to venous and arterial clots, lung scarring, worsening lung function, heart valve damage, and high blood pressure.

Pregnancy Outcomes

Lupus anticoagulant has a long track record of association with miscarriage, stillbirth, and serious pregnancy complications. In a prospective study of 1,237 pregnant women, a positive dRVVT-based lupus anticoagulant test independently predicted early-onset preeclampsia and intrauterine fetal death.

In a study of 526 high-risk pregnancies, dRVVT was the most sensitive single lupus anticoagulant assay, catching 36 of 40 persistently positive cases, more than any of the other available tests. It was particularly linked to sporadic stillbirth and thrombosis rather than recurrent early miscarriage alone.

Thrombosis and Vascular Risk

Beyond pregnancy, the test matters most for people who have already had an unexplained clot or who are being evaluated for clotting risk in autoimmune disease. A positive lupus anticoagulant can change how long anticoagulation is continued after a clotting event, which makes it a high-stakes result rather than a curiosity.

The clinical signal also depends on which dRVVT reagent and platform the lab uses. Some dRVVT formats correlate with venous thrombosis risk while others do not. This is one reason a single number, in isolation, should not drive a decision.

Why a Single Reading Can Fool You

The dRVVT screen is unusually sensitive to outside factors, and a single abnormal reading is not enough to act on. Re-testing after at least 12 weeks is standard practice when a positive result is found, because some antibodies are transient and tied to short-term illness rather than a true syndrome.

• Direct oral anticoagulants: rivaroxaban, dabigatran, apixaban, and edoxaban can distort the screen. In one mixed cohort of people on these drugs, 97.3% had an abnormal dRVVT screen overall, but the drug-specific picture is more nuanced. Rivaroxaban produces the highest false-positive rate (up to about 88% in one large cohort), dabigatran typically prolongs the screen as well, and apixaban can go in either direction, sometimes causing false negatives by affecting the confirm step more than the screen.
• Warfarin and heparin: vitamin K antagonists like warfarin can cause false positives, and high-dose unfractionated heparin (anti-Xa above 0.8 U/mL) can also distort results.
• Active inflammation: higher CRP has been associated with longer dRVVT clotting times, with the screen lengthening by about 0.11 seconds for every 1 mg/L rise in CRP in one analysis. Findings across the literature are mixed and depend heavily on the dRVVT reagent used, so the size of this effect is not settled. Even so, testing during an infection, after surgery, or in another acute illness can produce a misleading result.
• Lab and reagent differences: different dRVVT kits classify the same sample differently. One reagent labeled 11.5% of samples as positive while another labeled only 3.63% positive in the same dataset.

Reconciling a Confusing Result

It can feel paradoxical that an antibody called an anticoagulant predicts more clotting in the body, and that a screen designed to catch it is so easily thrown off by drugs that prevent clotting. The way to hold both ideas together is to remember that this is a phospholipid-dependence test, not a clotting-time test in the usual sense. It asks one specific question: does adding phospholipid back into the reaction shorten the clotting time? When the answer is yes, the inhibitor is the lupus anticoagulant. When the answer is no, the long clotting time is probably from a drug or another cause.

Tracking Over Time

This is not a marker to retest every year for general health monitoring. The standard approach is to confirm a positive result with a second test at least 12 weeks later, because antibodies that appear once during an illness often do not persist. Persistence over time is what matters for classifying antiphospholipid syndrome.

If your first dRVVT screen is positive, plan on a structured workup: a confirm test on the same draw, a paired lupus-sensitive aPTT or silica clotting time, and a full antiphospholipid antibody panel including anticardiolipin and anti-beta-2 glycoprotein I antibodies. Then a repeat at least 12 weeks later if any of those are positive. If you are on a blood thinner, your clinician may either pause the drug under supervision or use a method that removes drug interference before testing.

What to Do With an Out-of-Pattern Result

An abnormal dRVVT screen is the start of a workup, not the end of one. The result is most useful when interpreted alongside the confirm test, a mixing study, and a second LA-sensitive assay such as an LA-sensitive aPTT. No single assay catches every lupus anticoagulant, and pairing dRVVT with a complementary test is standard practice in specialized labs.

If your screen comes back prolonged, the practical next steps are: confirm that you are not on a direct oral anticoagulant or other drug that could distort the result, retest after at least 12 weeks to check for persistence, order a full antiphospholipid antibody panel (anticardiolipin IgG and IgM, anti-beta-2 glycoprotein I IgG and IgM), and bring the full set of results to a hematologist or coagulation specialist. If you have had a prior clot, stroke, or pregnancy loss, this combination drives decisions about long-term anticoagulation and pregnancy management. If you have not, persistent positivity may still change how aggressively other clotting risks are managed.

Who This Test Is For

This is a targeted test, not a screening test for healthy adults. There is no evidence that running a dRVVT screen on someone without symptoms or a personal or family history of clotting changes outcomes. It earns its place when there is a specific reason to look: an unexplained clot, repeated pregnancy loss, an autoimmune diagnosis, or stroke at a younger age than expected.